Incannex Healthcare (IXHL) Expected to Announce Quarterly Earnings on Friday

Incannex Healthcare (NASDAQ:IXHL) will likely be releasing its Q2 2026 results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($0.02) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, February 20, 2026 at 12:30 PM ET.

Incannex Healthcare (NASDAQ:IXHL) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.37. The business had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.20 million.

Incannex Healthcare Stock Performance

NASDAQ IXHL opened at $0.28 on Thursday. The company has a market capitalization of $96.56 million, a price-to-earnings ratio of -0.47 and a beta of 7.46. The company’s 50-day simple moving average is $0.37 and its two-hundred day simple moving average is $0.43. Incannex Healthcare has a one year low of $0.08 and a one year high of $1.88.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Incannex Healthcare in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Incannex Healthcare presently has an average rating of “Sell”.

Institutional Trading of Incannex Healthcare

A hedge fund recently raised its stake in Incannex Healthcare stock. LPL Financial LLC lifted its holdings in shares of Incannex Healthcare Inc. (NASDAQ:IXHL) by 639.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 335,373 shares of the company’s stock after acquiring an additional 290,000 shares during the period. LPL Financial LLC owned 0.10% of Incannex Healthcare worth $120,000 at the end of the most recent reporting period. 0.43% of the stock is owned by institutional investors and hedge funds.

Incannex Healthcare Company Profile

Incannex Healthcare Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.

The company’s research and development pipeline includes multiple product candidates in various stages of clinical evaluation.